| Literature DB >> 35676539 |
Bryan J Fraser1,2, Serap Beldar3, Almagul Seitova3, Ashley Hutchinson3, Dhiraj Mannar4, Yanjun Li3, Daniel Kwon1,2, Ruiyan Tan1, Ryan P Wilson1, Karoline Leopold4, Sriram Subramaniam4, Levon Halabelian5,6, Cheryl H Arrowsmith7,8,9, François Bénard10,11.
Abstract
Transmembrane protease, serine 2 (TMPRSS2) has been identified as key host cell factor for viral entry and pathogenesis of SARS-CoV-2. Specifically, TMPRSS2 proteolytically processes the SARS-CoV-2 Spike (S) protein, enabling virus-host membrane fusion and infection of the airways. We present here a recombinant production strategy for enzymatically active TMPRSS2 and characterization of its matured proteolytic activity, as well as its 1.95 Å X-ray cocrystal structure with the synthetic protease inhibitor nafamostat. Our study provides a structural basis for the potent but nonspecific inhibition by nafamostat and identifies distinguishing features of the TMPRSS2 substrate binding pocket that explain specificity. TMPRSS2 cleaved SARS-CoV-2 S protein at multiple sites, including the canonical S1/S2 cleavage site. We ranked the potency of clinical protease inhibitors with half-maximal inhibitory concentrations ranging from 1.4 nM to 120 µM and determined inhibitor mechanisms of action, providing the groundwork for drug development efforts to selectively inhibit TMPRSS2.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35676539 DOI: 10.1038/s41589-022-01059-7
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 16.174